Yu-Waye Chu
2021
In 2021, Yu-Waye Chu earned a total compensation of $6.5M as Chief Medical Officer at Fate Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $172,000 |
|---|---|
| Option Awards | $500,000 |
| Salary | $430,000 |
| Stock Awards | $5,375,416 |
| Total | $6,477,416 |
Chu received $5.4M in stock awards, accounting for 83% of the total pay in 2021.
Chu also received $172K in non-equity incentive plan, $500K in option awards and $430K in salary.
Rankings
In 2021, Yu-Waye Chu's compensation ranked 1,947th out of 12,406 executives tracked by ExecPay. In other words, Chu earned more than 84.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,947 out of 12,406 | 84th |
Division Manufacturing | 736 out of 5,494 | 87th |
Major group Chemicals And Allied Products | 282 out of 2,369 | 88th |
Industry group Drugs | 241 out of 2,090 | 89th |
Industry Biological Products, Except Diagnostic Substances | 73 out of 452 | 84th |
Source: SEC filing on April 25, 2022.
Chu's colleagues
We found five more compensation records of executives who worked with Yu-Waye Chu at Fate Therapeutics in 2021.
2021
J Wolchko
Fate Therapeutics
Chief Executive Officer
2021
Mark Plavsic
Fate Therapeutics
Chief Technology Officer
2021
Bahram Valamehr
Fate Therapeutics
Chief Research and Development Officer
2021
Cindy Tahl
Fate Therapeutics
General Counsel
2021
Edward Dulac
Fate Therapeutics